23andMe Ordered by the FDA to Halt Sales of Genetic Test

Google backed Genetic Test Maker 23andMe told to Halt Sales by the Food and Drug Administration (FDA) As most readers know, 23andMe offered genetic testing for free to further research for MPN patients.  A noble gesture indeed.  I readily participated and found the highly detailed report very thought provoking, but perhaps “missing the mark” in […]

The American Society of Hematology (ASH) Annual Meeting and Exposition 2013

2013 ASH Annual Meeting and Exposition- KEY ABSTRACTS for Myeloproliferative Neoplasms December 7-10, 2013 – Ernest N. Morial Convention Center, New Orleans, LA   Myeloproliferative Neoplasms Absracts Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients Increased Platelet Thrombus Formation Under Flow […]

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

Key points The sensitivity and specificity of detecting the JAK2 p.V617F mutation in peripheral blood are both 100% compared to bone marrow. The JAK2 p.V617F allele burden measured in peripheral blood is equivalent to that in bone marrow aspirate (R2=0.991; P<0.0001). See the Abstract Here

Dr Silver on the Curability of Polycythemia Vera with Interferon

Dr. Richard Silver delivers a stellar presentation – On the “Curability” of Polycythemia Vera with Interferon. Presented February 2013, Mayo Clinic, Scottsdale, Arizona.   Richard Silver PV

error: Content is protected !
Malcare WordPress Security